Skip to main content
Fig. 2 | BMC Research Notes

Fig. 2

From: Prognostic significance of hepatocyte growth factor activator inhibitor type 1 (HAI-1) immunoreactivity in pancreatic ductal adenocarcinoma

Fig. 2

Immunoreactivity of HAI-1 in invasive PDAC cells. a, b Representative examples of diffuse immunoreactivity in cancer cells (score 3). Cell surface immunoreactivity of HAI-1 is evident. Bar, 250 μm (a) or 50 μm (b). c, d Reduction of HAI-1 immunoreactivity is present in some (c, score 2) or majority of (d, score 1) PDAC cells, showing intratumoral HAI-1 heterogeneity. Bar, 50 μm (c) or 100 μm (d). e Representative photo of HAI-1 negative case. Bar, 100 μm. f, g Association of diffuse HAI-1 immunoreactivity in PDAC cells to patient prognosis. Kaplan–Meier survival curves for DFS (f). Patients with diffusely positive HAI-1 staining (score 3, n = 39, total events 22) had favorable DFS compared with those with partial HAI-1 (score 1 + 2, n = 28, total events 25) (p = 0.006). Kaplan–Meier survival curves for OS (g). No significant difference was observed (p = 0.413). Total events are 22 and 28 for score 3 and score 1 + 2, respectively. p value was calculated by log-rank test. ┼censored cases

Back to article page